Transactions in the Exosome Space
JUNE 2020: PRE-CLINICAL
Eli Lilly and Evox announced a $1.2 billion collaboration to apply exosome technology to delivery of RNA interference and antisense oligonucleotide drugs, to reach central nervous system targets.
Evox received $20 million upfront and is eligible to receive up to a total of $1.2 billion in direct investments, milestones & royalties.
MARCH 2020: PRE-CLINICAL
Takeda and Evox announced a collaboration to utilize Evox’s exosome technology to develop candidates for rare brain-related diseases. Evox received $44M upfront and is eligible to receive up to $838M in milestone & royalty payments.
JANUARY 2019: PRE-CLINICAL
Jazz licensed Codiak Biosciences’ exosome technology to develop up to 5 cancer candidates.
Codiak received $56M upfront and is eligible to receive up to $20M in pre-clinical milestones, and up to US$200M in milestone-based payments for each of the 5 candidates. Royalty payments are upside to this agreement.
JULY 2018 STAGE: PRE-CLINICAL
Roche licensed PureTech’s exosome technology to develop oral antisense candidates.
PureTech received $36M upfront and is eligible to receive over $1 billion in milestone-based and royalty payments.